| 摘要 |
<p>Tetrazole derivs. of formula (I), their physiologically acceptable salts, hydrates and bioprecursors are new: In (I) (R1 is 1-14C alkyl, cycloalkyl, aralkyl, trifluoroalkyl, heteroalkyl, alkenyl, alkynyl or is alkyl substd. by hydroxy, alkoxy, amino(opt. mono or di-alkyl substd.) or cycloalkyl. R2 is H or 1-4C alkyl, or R1 and R2 together form a 5-10 membered ring which is satd. or contains at least one double bond, and is opt. substd. by one or more 1-3C alkyl or a hydroxy, and -or contains an additional O or S ring atom. Alk is 1-6C, opt. branched, alkylene. Q is 2,5-linked furan or thiophene, opt. substd. by R4 adjacent to R1R2N.Alk-; or is 2,4-linked thiophene opt. similarly substd. provided that if R1R2NAlk-is at 4 position, R4 is at 5-position; or Q is 1,3- or 1,4-phenylene. R4 is halo or 1-4C alkyl(opt. substd. by hydroxy or 1-4C alkoxy). R3 is H, alkyl, alkenyl, aralkyl or is 2-6C alkyl substd. by hydroxy, alkoxy or 1-4C alkanoyloxy. X and Y are O, S, methylene or a bond. n is zero to 3. m is 2-5, provided that the total no. of atoms in X(CH2)nY(CH2)m is 3-8, and if X and Y are O or S then n is 2 or 3. (I) are selective inhibitors of the H2-receptors so are useful e.g. for treating peptic or gastric ulcers, allergies, inflammation, etc. Pref. they are administered orally at 5-500 mg. per day.</p> |
